Thomas Makatsoris

TL;DR: The spectrum of chemotherapy-induced peripheral neuropathy characteristics is discussed so as to highlight areas of future research to pursue on the topic and allow the registration and analysis of reliable data on the true characteristics of CIPN, eventually leading to potential preventive and therapeutic interventions.

TL;DR: BRAF and codon 12 KRAS mutations predict for adverse outcome of CRC patients receiving cetuximab, and high AREG mRNA reflects EGFR signalling in KRAS wild type tumours, predicting for cetUXimab efficacy when high and failure when low.

TL;DR: The incidence of OxIN was strikingly decreased in patients receiving oxcarbazepine and may prevent OxIN symptoms, and further larger placebo-controlled trials are warranted to confirm the results.

TL;DR: The results indicate that the majority of patients treated with the FOLFOX-4 regimen would manifest an axonal, predominately sensory peripheral neuropathy, of mild to moderate severity.

TL;DR: Considering the antitumor activity and response duration, the negligible toxicity of the highest dose investigated and the lack of drug accumulation over time, it is suggested that 50 mg given three times a week is the optimal dose for metronomic oral vinorelbine.